Resmetirom Is a New Rx for Liver Inflammation and Scarring
July 2024
Resmetirom (Rezdiffra) will be a new Rx for a severe form of fatty liver disease not due to alcohol...or nonalcoholic steatohepatitis (NASH).
About 5% of adults in the US have NASH. These patients have a buildup of fat in the liver...which leads to inflammation and scarring.
Until now, treatment for NASH has mainly involved making lifestyle changes...and managing conditions such as diabetes and high cholesterol.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote